I really have no idea where the markets are going. In fact, I'm surprised and dumbfounded how the markets have surged to these levels at all. Never doubt the power behind the FED and the massive CASH print machine. Are we in danger zone? Not Yet!. Watch for a break of 17,000 on the INDU. It [...]
NPS up 80% from October - Some secrets obviously don't stay in the board room? Shire and NPS Pharmaceuticals, announced that the companies have entered into a merger agreement pursuant to which Shire will acquire all the outstanding shares of NPS Pharma for $46.00 per share in cash, for a total consideration of approximately $5.2 [...]
VRTX - 44% Ramp from August - How much more of a Premium for a Pharma bid? NEW YORK (TheStreet) -- My biotech stock predictions for 2015. (BY David Sobek) 1. Drug pricing fears finally catch up to the biotech sector and the multi-year bull market ends. However, the closely watched biotech stock indices churn up [...]
By Emily Wasserman A new voice is joining the patent-fighting chorus. U.S. hedge fund manager Kyle Bass, best known for predicting the subprime mortgage crisis in 2008, said he plans to challenge "questionable" drug patents held by industry heavyweights. Bass plans to challenge 15 drug companies' patents via an Inter Partes Review (IPR) process created [...]
Upside traction in the Pharma's indicate plenty of capital for R&D...
by Anette Breindl, PhD Twenty-four years after the National Institutes of Health (NIH) established the Office of Research on Women’s Health, and 21 years after the NIH Revitalization Act of 1993 first required that women be included in clinical trials, certainly the letter of the law has been achieved. Women are now the majority of participants [...]
CytomX Therapeutics Inc. grabbed $20 million led by Pfizer Inc.'s venture capital arm to help partner its sneaky cancer fighters with new types of drugs and build out its own portfolio. The investment, disclosed Tuesday, comes after CytomX on Monday announced a trio of key hires, including former Five Prime Therapeutics chief scientific officer Dr. [...]
What does Crude Oil have to do with Pharma? As oil plunges, so does the capital needed for R&D.
By Tracy Staton The shake-up at the top of Salix Pharmaceuticals continues. On Monday afternoon, CEO Carolyn Logan became the second C-suite executive to step down in the wake of an inventory snafu disclosed late last year. Logan will retire as of Jan. 30, the company said. CFO Adam Derbyshire made his exit in [...]
